Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A4 | P31645 | 3/20 | 0.36 |
| ▸ | SLC6A3 | Q01959 | 3/20 | 0.36 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.36 |
| ▸ | OPRM1 | P35372 | 2/20 | 0.34 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.34 |
| ▸ | OPRL1 | P41146 | 1/20 | 0.34 |
| ▸ | PNMT | P11086 | 1/20 | 0.33 |
| ▸ | MAOA | P21397 | 1/20 | 0.33 |
| ▸ | MAOB | P27338 | 1/20 | 0.33 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | DPP4 | P27487 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL968174 | 0.84 | HDAC4 (0.42) | HDAC4OPRM1OPRK1OPRL1PNMT | |
| SCHEMBL22661007 | 0.76 | OPRM1 (0.46) | SLC6A4SLC6A3HDAC4OPRM1OPRK1 | |
| SCHEMBL2969527 | 0.74 | OPRM1 (0.44) | OPRM1OPRK1OPRL1PNMTMAOA | |
| SCHEMBL29976718 | 0.71 | OPRM1 (0.39) | SLC6A4SLC6A3HDAC4OPRM1OPRK1 | |
| SCHEMBL15954140 | 0.70 | DPP4 (0.41) | SLC6A4SLC6A3OPRM1OPRK1OPRL1 | |
| SCHEMBL8330377 | 0.70 | OPRM1 (0.37) | SLC6A4SLC6A3OPRM1OPRK1OPRL1 | |
| SCHEMBL7192009 | 0.69 | SLC6A4 (0.47) | SLC6A4SLC6A3OPRM1DPP4 | |
| SCHEMBL7356520 | 0.66 | PNMT (0.44) | HDAC4PNMTMAOAMAOB | |
| SCHEMBL8330382 | 0.65 | OPRM1 (0.61) | OPRM1OPRK1OPRL1MEN1CYP2C9 | |
| SCHEMBL3898162 | 0.62 | MAOA (0.47) | SLC6A4SLC6A3OPRM1OPRL1MAOA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2451793-B1 | BACE INHIBITORS | LILLY CO ELI (US) | 2016-11-02 | — | — | EP | disclosed |
| US-20120323001-A1 | BACE INHIBITORS | ELI LILLY AND COMPANY (US) | 2012-12-20 | — | — | US | disclosed |
| US-8278441-B2 | BACE inhibitors | ELI LILLY AND COMPANY (US) | 2012-10-02 | — | — | US | disclosed |
| US-20110009395-A1 | BACE INHIBITORS | ELI LILLY AND COMPANY (US) | 2011-01-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120323001-A1 | BACE INHIBITORS | BACE1, BACE2, APP | SLC6A4 3355/4885SLC6A3 1985/4885HDAC4 3363/4885 |
| US-20110009395-A1 | BACE INHIBITORS | BACE1, BACE2, APP | SLC6A4 3355/4885SLC6A3 1985/4885HDAC4 3363/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.